01:46 PM EDT, 07/25/2024 (MT Newswires) -- Becton, Dickinson ( BDX ) and Quest Diagnostics ( DGX ) said Thursday they are collaborating to develop, manufacture and commercialize flow cytometry-based companion diagnostics for cancer and other diseases.

The companies said they will aim to provide the pharmaceutical industry with joint offerings ranging from exploratory panel development to the manufacturing and distribution of diagnostic kits.

Flow cytometry is a laboratory technology that can provide insight on a patient's immune response and how to best manage treatment, according to the companies. Financial details were not provided.

Price: 234.93, Change: -2.41, Percent Change: -1.02